Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 267

The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.

Introduction: Methods, Commentary, and Summary

ALLEN, MICHAEL H., CURRIER, GLENN W., CARPENTER, DANIEL, ROSS, RUTH W., DOCHERTY, JOHN P.·2005·Journal of Psychiatric Practice

Abstract

OBJECTIVES: Due to inherent dangers and barriers to research in emergency settings, few data are available to guide clinicians about how best to manage behavioral emergencies. Key constructs such as agitation are poorly defined. This lack of empirical data led us to undertake a survey of expert opinion, results of which were published in the 2001 Expert Consensus Guidelines on the Treatment of Behavioral Emergencies. Several second-generation (atypical) antipsychotics (SGAs) are now available in new formulations for treating behavioral emergencies (e.g., intramuscular [i.m.] olanzapine and ziprasidone; rapidly dissolving tablets of olanzapine and risperidone). Critical questions face the field. The SGAs are significantly different from the FGAs and from each other and have not been studied in unselected patients as were the FGAs. Can the SGAs can be thought of as a class, do all antipsychotics have similar anti-agitation effects in different conditions, and, if equally effective, what limits might their safety profiles impose? Should antipsychotics be used more specifically to treat psychotic conditions, while benzodiazepines (BNZs) alone are used nonspecifically? Few data are available concerning combinations of SGAs and BNZs, and findings concerning the traditional combination of haloperidol plus a BNZ may not be relevant to combinations with SGAs. The culture is also evolving with more emphasis on patient involvement in treatment decisions. An international consensus has been developing that calming rather than sedation is the appropriate endpoint of behavioral emergency interventions. We undertook a new survey of expert opinion to update recommendations from the earlier survey. METHOD: A written survey of 61 questions (1,020 options) was mailed to 50 experts in the field, 48 (96%) of whom completed it. The survey sought to define level of agitation at which emergency interventions are appropriate, scope of assessment depending on urgency and patients' ability to cooperate, guiding principles for selecting interventions, and appropriate physical and medication strategies at different levels of diagnostic confidence for a variety of provisional diagnoses and complicating conditions. A modified version of the RAND Corporation's 9-point scale for rating appropriateness of medical decisions was used to score most options. Consensus was defined as a non-random distribution of scores by chi-square "goodness-of-fit" test. We assigned a categorical rank (first line/preferred, second line/alternate, third line/usually inappropriate) to each option based on the 95% confidence interval around the mean. Ratings were used to develop guidelines for preferred strategies in key clinical situations. This study received financial support from multiple sponsors, with the panel kept blind to sponsorship to reduce possible bias. Medication ratings were based on responses of only those respondents with direct experience with each drug. In reporting practice patterns, the panel was asked to respond based on actual data rather than estimates. RESULTS: The expert panel reached consensus on 78% of the options rated on the 9-point scale. The responses suggest that physicians can make provisional diagnoses with some confidence and that pharmacological and nonpharmacological interventions are selected differentially based on diagnosis and other salient demographic and medical features. BNZs are recommended when no data are available, when there is no specific treatment (e.g., personality disorder), or when they may have specific benefits (e.g., intoxication). No single SGA emerges as a nonspecific replacement for haloperidol; instead, different SGAs are preferred in various circumstances consistent with current evidence. To the degree that haloperidol is recommended, it is almost always in combination with a BNZ; haloperidol alone is preferred only in the medically compromised. In contrast, the SGAs are more often recommended for use alone, and the panel would avoid combining BNZs with some SGAs. Oral risperidone alone or combined with a BNZ receives strong support in a variety of situations. Oral olanzapine was rated very similarly to risperidone, with slightly higher ratings than risperidone in situations where it has been studied (e.g., schizophrenia, mania) and slightly lower ratings where it has not been studied or safety may be a concern; there was less support for combining oral olanzapine with a BNZ. For oral treatment of agitation related to schizophrenia or mania, olanzapine alone, risperidone alone or combined with a BNZ, and haloperidol plus a BNZ are first line, with strong support also for combining divalproex with the antipsychotic for presumed mania. Oral ziprasidone and quetiapine generally received similar second-line ratings in most situations. If a parenteral agent is needed, i.m. olanzapine alone received somewhat more support than i.m. ziprasidone alone; however, there was more support for i.m. ziprasidone alon

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00131746-200511001-00002

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 75 references

Research works printed but not linked: 31

  1. Djulbegovic, 1998, Oncology, 12, 310
  2. Kahn, 1996, J Clin Psychiatry, 57, 1
  3. McEvoy, 1996, J Clin Psychiatry, 57, 1
  4. March, 1997, J Clin Psychiatry, 58, 1
  5. McEvoy, 1999, J Clin Psychiatry, 60, 1
  6. Foa, 1999, J Clin Psychiatry, 60, 1
  7. Rush, 2000, AJMR, 105, 159
  8. Conners, 2001, J Atten Disord, 4, S1
  9. Kane, 2003, J Clin Psychiatry, 64, 1
  10. Alexopoulos, 2004, J Clin Psychiatry, 65, 1
  11. Kahn, 1997, Psychopharmacol Bull, 33, 631
  12. Copersino, 2003, Psychiatr Serv, 54, 314, 10.1176/appi.ps.54.3.314 · doi:10.1176/appi.ps.54.3.314
  13. Martel, 2003, Acad Emerg Med, 10, 510, 10.1197/aemj.10.5.510-b · doi:10.1197/aemj.10.5.510-b
  14. Currier, 2000, J Clin Psychiatry, 61, 21
  15. Salzman, 1991, J Clin Psychiatry, 52, 177
  16. Currier, 2001, J Clin Psychiatry, 62, 153, 10.4088/JCP.v62n0303 · doi:10.4088/jcp.v62n0303
  17. Daniel, 2004, Int Clin Psychopharmacol, 19, 9, 10.1097/00004850-200401000-00002 · doi:10.1097/00004850-200401000-00002
  18. Reschke, 1974, Dis Nerv Sys, 35, 112
  19. Hatta, 2002, Psychiatr Serv, 53, 1077, 10.1176/appi.ps.53.9.1077 · doi:10.1176/appi.ps.53.9.1077
  20. Bourdinaud, 2003, Encephale, 29, 89
  21. Stotsky, 1977, yst, 38, 967
  22. Binder, 1981, J Clin Psychiatry, 42, 203
  23. Paprocki, 1977, Curr Ther Res Clin Exp, 21, 80
  24. Tuason, 1986, J Clin Psychiatry, 47, 126
  25. Gerstenzang, 1977, Dis Nerv Syst, 38, 581
  26. Brook, 2000, J Clin Psychiatry, 61, 933, 10.4088/JCP.v61n1208 · doi:10.4088/jcp.v61n1208
  27. Preval, 2005, Gen Hosp Psychiatry, 27, 140, 10.1016/j.genhosppsych.2004.11.004 · doi:10.1016/j.genhosppsych.2004.11.004
  28. Scahill, 2005, J Psychopharmacol, 19, 205, 10.1177/0269881105049042 · doi:10.1177/0269881105049042
  29. Wyant, 1990, Psychopharmacol Bull, 26, 126
  30. Chouinard, 1993, Can J Psychiatry, 38, S114
  31. Salzman, 1988, J Clin Psychiatry, 49, 13

Cited by

See all 267

Metadata

Authors
ALLEN, M. H., CURRIER, G. W., CARPENTER, D., ROSS, R. W., & DOCHERTY, J. P.
Venue
Journal of Psychiatric Practice
Published
2005-11
Volume
11
Pages
5-25
ISSN
  • 1527-4160 (ISSN-L)
  • 1538-1145
OpenAlex
W2086011500
Cited by
267
References
75
FWCI
7.15
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Introduction: Methods, Commentary, and Summary. https://app.cochat.ai/papers/10.1097/00131746-200511001-00002
The paper
ALLEN, M. H., CURRIER, G. W., CARPENTER, D., ROSS, R. W., & DOCHERTY, J. P. (2005). Introduction: Methods, Commentary, and Summary. Journal of Psychiatric Practice. https://doi.org/10.1097/00131746-200511001-00002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.